American Society of Clinical Oncology-54th Annual Meeting

被引:0
|
作者
Kibble, A. [1 ]
Al-Shamahi, A. [1 ]
Kuenneman, K. [1 ]
机构
[1] Clarivate Analyt, London, England
关键词
AG-881; Ibrutinib; TAK-931; BAY-1251152; LOXO-292; Moxetumomab pasudotox; Celyvir; NKTR-214; Taselisib; Ribociclib; Hu5F9-G4; Niraparib; CX-072; Bevacizumab; Atezolizumab; BI-836880; Durvalumab;
D O I
10.1358/dof.2018.043.08.2866112
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The theme for this year's ASCO annual meeting is centered around expediting cancer research breakthroughs through expansion of the reach of precision medicine, which set an exciting tone as the meeting got underway in a typically busy fashion. Precision medicine is transforming cancer care in profound ways, and this focus is sure to highlight the importance of using molecular, clinical or histopathological data to inform the best tailored therapy for every patient with cancer. The meeting saw almost 40,000 attendees from around the world gather to hear the latest innovations and developments in cancer care across diverse and wide-ranging disciplines and treatment approaches, which will undoubtedly lead to practice-changing care for patients with a cancr diagnosis.
引用
收藏
页码:617 / 626
页数:10
相关论文
共 50 条